Table 4.
Pooled and Meta-Analysis for PFS
| Parameter | Pooled Analysis (n = 530) |
Meta-Analysis (random effect; n = 342) |
||||||
|---|---|---|---|---|---|---|---|---|
| Univariable |
Multivariable |
Univariable |
Multivariable |
|||||
| Median (months; 95% CI) | P* | t | P† | Median (months; 95% CI) | P‡ | z | P§ | |
| Total studies | 3.0 (2.8 to 3.2) | 3.0 (2.9 to 3.1) | ||||||
| Personalized strategy | < .001 | 8.7 | < .001 | < .001 | 11.1 | < .001 | ||
| Yes | 6.8 (5.3 to 7.6) | 5.9 (5.4 to 6.3) | ||||||
| No | 2.8 (2.7 to 3.0) | 2.7 (2.6 to 2.9) | ||||||
| Chemotherapy status | < .001 | 5.6 | < .001 | < .001 | 5.3 | < .001 | ||
| Chemotherapy naïve | 3.0 (2.6 to 4.5) | 4.7 (4.1 to 5.2) | ||||||
| Prior chemotherapy | 2.8 (2.7 to 3.0) | 2.8 (2.7 to 2.9) | ||||||
| Tumor type | < .001 | 7.4 | < .001 | < .001 | 5.6 | < .001 | ||
| Solid | 2.9 (2.7 to 3.0) | 2.9 (2.8 to 3.0) | ||||||
| Hematologic | 5.4 (4.0 to 9.0) | 5.9 (4.7 to 7.0) | ||||||
| Agent class | .281 | — | — | .012 | 4.9 | < .001 | ||
| Cytotoxic | 3.3 (3.0 to 3.7) | 3.3 (3.0 to 3.5) | ||||||
| Targeted | 2.9 (2.7 to 3.0) | 2.9 (2.9 to 3.0) | ||||||
| Study design | .250 | — | — | .114 | — | — | ||
| Randomized | 2.8 (2.6 to 3.1) | 3.0 (2.7 to 3.3) | ||||||
| Nonrandomized | 3.0 (2.8 to 3.4) | 3.0 (2.9 to 3.1) | ||||||
| 5-Year impact factor‖ | .001 | 0.4 | .662 | < .001 | 4.4 | < .001 | ||
| ≤ 10 | 2.9 (2.7 to 3.0) | 2.8 (2.7 to 2.9) | ||||||
| > 10 | 3.8 (3.3 to 4.6) | 4.1 (3.7 to 4.4) | ||||||
| No. of patients per arm¶ | .021 | 1.0 | .334 | < .001 | 2.0 | .041 | ||
| ≤ 35 | 2.8 (2.5 to 3.0) | 2.7 (2.6 to 2.8) | ||||||
| > 35 | 3.3 (2.9 to 3.6) | 3.2 (3.1 to 3.4) | ||||||
| Administration route | < .001 | 0.1 | .908 | < .001 | 3.9 | < .001 | ||
| Oral | 3.5 (3.0 to 3.8) | 3.2 (3.1 to 3.4) | ||||||
| Injection | 2.8 (2.6 to 3.0) | 2.8 (2.6 to 2.9) | ||||||
| FDA/EMA approval | < .001 | 2.2 | .030 | < .001 | 2.0 | .050 | ||
| No | 2.7 (2.1 to 2.9) | 2.6 (2.4 to 2.7) | ||||||
| Yes | 3.1 (2.9 to 3.5) | 3.2 (3.1 to 3.4) | ||||||
| No. of treating centers | .357 | — | — | .353 | — | — | ||
| Single center | 2.9 (2.5 to 3.4) | 2.9 (2.6 to 3.1) | ||||||
| Multiple centers | 3.0 (2.8 to 3.3) | 3.1 (2.9 to 3.2) | ||||||
NOTE. Only variables that were significant in the univariable models were included in the multivariable analysis. The t and z values are used to compute the corresponding P values, and the higher they are, the more they contribute to the model. The pooled analysis included 530 arms, and the meta-analysis included 342 arms for which median PFS and the corresponding 95% CI values were available.
Abbreviations: EMA, European Medicines Agency; FDA, US Food and Drug Administration; PFS, progression-free survival.
Wilcoxon test; the median in the univariable was not weighted.
Multiple linear regression model using a weighted least squares model.
Mixed effects analysis.
Random effects meta-regression model.
Cutoff value chosen to discriminate higher impact factor journals versus lower impact factor journals (sum of median and interquartile range).
Cutoff value used was the median of distribution.